A phase I trial of oxaliplatin and topotecan in recurrent ovarian carcinoma

John C. Elkas*, William E. Winter, Mildred R. Chernofsky, Jan Sunde, Michael A. Bidus, Sarah Bernstein, G. Scott Rose

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Objective.: Oxaliplatin and topotecan have demonstrated activity as single agents against recurrent platinum-sensitive and -resistant ovarian cancer, as well as synergy in vitro. This was a dose-finding study of combination therapy with weekly topotecan and alternating-week oxaliplatin in patients with recurrent epithelial ovarian cancer. Methods.: Eligible patients had a diagnosis of recurrent ovarian or primary peritoneal carcinoma, a performance status of 0-2, and normal bone marrow, renal, and hepatic function. On days 1 and 15 of a 28-day cycle, patients received a fixed dose of oxaliplatin (85 mg/m2) via intravenous infusion. On days 1, 8, and 15, patients received an escalating dose of intravenous topotecan (2.0-4.0 mg/m2). Five dose levels were planned with a minimum cohort of 3 patients at each level. Results.: Thirteen patients were enrolled and received a total of 50 cycles of chemotherapy. The maximum tolerated dose was 85 mg/m2 of oxaliplatin and 3.0 mg/m2 of topotecan, and grade 3 neutropenia was the dose-limiting toxicity. Four of nine (44%) evaluable patients had stable disease or a partial response to the drug combination as assessed by cancer antigen-125 levels. Conclusions.: A 28-day schedule of oxaliplatin and topotecan is safe and well tolerated. Because of the in vitro synergy observed between topoisomerase I inhibitors and platinum derivatives and the tolerability reported in the current study, this regimen warrants further investigation.

Original languageEnglish
Pages (from-to)422-427
Number of pages6
JournalGynecologic Oncology
Issue number2
StatePublished - Feb 2007
Externally publishedYes


  • Ovarian cancer
  • Oxaliplatin
  • Phase I
  • Topotecan


Dive into the research topics of 'A phase I trial of oxaliplatin and topotecan in recurrent ovarian carcinoma'. Together they form a unique fingerprint.

Cite this